Summary

Overview
Global Hypovolemic Shock Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Hypovolemic shock is an emergency condition in which severe blood or other fluid loss makes the heart unable to pump enough blood to the body. This type of shock can cause many organs to stop working. Numerous factors, such as severe bleeding, dehydration, burns, vomiting, diarrhoea, or extreme perspiration, might contribute to this syndrome. Hypovolemic shock necessitates quick medical attention and, if untreated, can be lethal.
Intravenous (IV) fluids are frequently used as a treatment for hypovolemic shock in order to quickly increase blood volume and lower blood pressure. Blood transfusions may be required in circumstances of severe bleeding. It's also essential to determine and treat the shock's underlying causes, such as treating dehydration or halting bleeding.
Market Dynamics: Drivers and Restraints
The rising research and development on hypovolemic shock treatment
The expansion of the worldwide hypovolemic shock treatment market is anticipated to be driven by an increase in research and development in this field. For instance, Pharmazz, Inc. reported in September 2021 that the US FDA had authorised the Phase III clinical research of the drug candidate centhaquine it had conducted for the management of hypovolemic shock.
The primary endpoint of the Phase III clinical investigation, which will involve 430 patients randomly divided equally into both arms, will be 28-day mortality. It will be a multi-centric, double-blind, placebo-controlled trial. Enrollment in Pharmazz should start towards the end of 2021 or the start of 2022.
Serious wounds from collisions, falls, or other types of trauma can also result in rapid and significant blood loss, which can produce hypovolemic shock. Severe dehydration decreases the body's fluid volume, which also lowers blood volume. Vomiting, diarrhoea, excessive perspiration, or a lack of fluid intake, particularly in hot weather or after vigorous exertion, can cause the disease and thus above factors helps to boost the market growth.
Market Dynamics: Restraint
A hospital setting is required for prompt treatment of hypovolemic shock, which is a medical emergency. The healthcare system may have restraints or impediments that affect the management or treatment of hypovolemic shock. For instance, it may be difficult to treat hypovolemic shock effectively if there is insufficient access to medical facilities or a delay in receiving assistance.
Additionally, in some areas, particularly in poor nations, a lack of well outfitted medical facilities, qualified medical staff, or sufficient medical supplies may make it difficult to treat hypovolemic shock in a timely and effective manner. Receiving prompt and proper medical care can be hampered by high healthcare expenses, particularly for those without health insurance or in areas where healthcare is not publicly financed.
For more details of the report, Request for sample
Segment Analysis
The global hypovolemic shock market is segmented based on type, treatment, route of administration, end-user and region.
The hemorrhagic shock segment from the type segment accounted for approximately 49.7% of hypovolemic market
When a person experiences significant bleeding, hemorrhagic shock, a potentially fatal illness, develops. This condition necessitates quick attention and treatment because it is a medical emergency. Vital organs like the brain, heart, kidneys, and liver receive oxygen and nourishment through the blood.
The decreased blood supply in hemorrhagic shock deprives these organs of oxygen and nutrients, resulting in organ dysfunction or failure.The heart's ability to pump blood efficiently is impacted by insufficient blood volume. Heart rhythm irregularities, a reduction in cardiac output, and ultimately cardiac arrest can result from this. A high fatality rate is associated with hemorrhagic shock, particularly if it is not promptly and efficiently treated.
To increase the likelihood of life, quick intervention, such as fluid replacement, blood transfusions, and surgical control of bleeding, is necessary. Hemorrhagic shock is often avoidable, especially in trauma-related instances. Hemorrhagic shock-related mortality can be avoided with the help of quick medical intervention, better trauma treatment, and public education.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
In terms of revenue share during the forecast period, North America is anticipated to dominate. Increasing healthcare spending, improving healthcare facilities, increased demand for disease-specific treatments, increased emphasis on research and development, and an increase in the number of FDA-approved medications for treating hypovolemic shock are all contributing factors to the healthcare sector's rapid technological evolution.
For instance, the American Medical Association (AMA) estimates that health spending in the U.S. increased by 2.7% in 2021 to $4.3 trillion, or $12,914 per person. This growth rate is considerably less than the 2020 growth forecast (10.3%%). This significant slowdown in spending can be linked to a drop in government spending on pandemic-related expenses countering an increase in the use of medical supplies and services that recovered from 2020 owing to delayed care and pent-up demand. Thus, the increase in healthcare spending will accelerate the region's economic development.
Due to increased healthcare costs in emerging nations and a growth in demand for hypovolemic shock treatment, Asia Pacific is anticipated to grow at a high revenue CAGR over the projected period. The region's market is driven by factors such as an ageing population, growing healthcare awareness, and prominent manufacturers focusing more on developing nations like China and India.
COVID-19 Impact Analysis
Blood clots and other aberrant coagulation processes have both been linked to COVID-19. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are two disorders that can occur when these blood clots block important blood veins. These coagulation abnormalities have the potential to cause considerable bleeding and hypovolemic shock if they are severe and widespread. Sepsis, a disorder that can be fatal that is brought on by an unbalanced immunological response to infection, can result from severe COVID-19 cases.
Sepsis can cause extensive inflammation and leaky blood vessels, which can lead to fluid loss and perhaps hypovolemic shock. Medical attention for situations other than COVID-19, such as trauma cases, was delayed during the pandemic's peak because some regions' healthcare systems were overburdened. Hypovolemia may develop from delaying the treatment of severe wounds or internal bleeding.
Market Segmentation
By Type
• Hemorrhagic
• Non-hemorrhagic
By Treatment
• Medication
o Epinephrine
o Norepinephrine
o Dopamine
o Dobutamine
• Therapy
By Route of Administration
• Oral
• Intravenous
By End-User
• Hospitals
• Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc, Viatris Inc, AstraZeneca Pharma Ltd, Wellona Pharma Ltd, Baxter Inc, Anant Pharmaceuticals Pvt. Ltd, REWINE PHARMACEUTICAL, Hikma Pharmaceuticals, PLC, LEXICARE PHARMA PVT. LTD, Taj Pharma Group and among others.
Why Purchase the Report?
• To visualize the global hypovolemic shock market segmentation based on type, treatment, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hypovolemic shock market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hypovolemic shock market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by End-User
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising research and development on hypovolemic shock treatment
4.1.1.2. Increasing product approvals
4.2. Restraints
4.2.1.1. Limited access to healthcare facilities
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Hemorrhagic *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-hemorrhagic
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Medication *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Epinephrine
8.2.4. Norepinephrine
8.2.5. Dopamine
8.2.6. Dobutamine
8.3. Therapy
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Viatris Inc
13.3. AstraZeneca Pharma Ltd
13.4. Wellona Pharma Ltd
13.5. Baxter Inc
13.6. Anant Pharmaceuticals Pvt. Ltd
13.7. REWINE PHARMACEUTICAL
13.8. Hikma Pharmaceuticals PLC
13.9. LEXICARE PHARMA PVT. LTD
13.10. Taj Pharma Group
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us